A drug that binds with high affinity but does not trigger full system activation is best described as which?

A drug that binds with high affinity but does not trigger full system activation is best described as which?

• A. Partial agonist.
• B. Full agonist.
• C. Antagonist.
• D. Inverse agonist.

Answer: (A)

This item tests the difference between how tightly a drug binds to a receptor (affinity) and how strongly it activates the receptor (efficacy). A drug that binds very well but does not produce a full response has high affinity but low intrinsic activity. That combination defines a partial agonist: it can occupy receptors readily, but the maximum effect it can produce is only a portion of what a full agonist would achieve. In other words, even with all receptors bound, the response is submaximal. For contrast, a full agonist would produce the maximal possible response; an antagonist binds without activating and mainly blocks other drugs from activating the receptor; and an inverse agonist reduces baseline (constitutive) receptor activity. A useful nuance is that a partial agonist can act like a blocker in the presence of a full agonist, limiting the overall effect by competing for receptor sites.

This item tests the difference between how tightly a drug binds to a receptor (affinity) and how strongly it activates the receptor (efficacy). A drug that binds very well but does not produce a full response has high affinity but low intrinsic activity. That combination defines a partial agonist: it can occupy receptors readily, but the maximum effect it can produce is only a portion of what a full agonist would achieve. In other words, even with all receptors bound, the response is submaximal.

For contrast, a full agonist would produce the maximal possible response; an antagonist binds without activating and mainly blocks other drugs from activating the receptor; and an inverse agonist reduces baseline (constitutive) receptor activity. A useful nuance is that a partial agonist can act like a blocker in the presence of a full agonist, limiting the overall effect by competing for receptor sites.